Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2020-11-04 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to third quarter 2020 results presentation
Report Publication Announcement Classification · 98% confidence The document is titled "PCI Biotech: Invitation to third quarter 2020 results presentation". It explicitly states that the 'third quarter 2020 interim report will be released on 11 November 2020' and that a 'results presentation... will be held through a webcast'. The document itself is an announcement about the upcoming release of the interim report and the associated presentation/webcast, not the full interim report or the presentation slides themselves. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report or presentation will be published or made available points towards a Report Publication Announcement (RPA). Since it announces the release of the interim report and the presentation, RPA is the most fitting category.
2020-11-04 English
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
Regulatory Filings Classification · 100% confidence The document is a short announcement (4237 characters) dated October 26, 2020, detailing a specific operational milestone: the enrollment of the first Asian patient in the pivotal RELEASE study for fimaChem. It provides contact information, details about the study design (EMA/FDA meetings, endpoints), and background on the company (PCI Biotech). This is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER) which typically contains summarized financial tables. It is a specific, material operational update that doesn't fit the definitions for Capital/Financing (CAP), Director's Dealing (DIRS), or Dividend (DIV). Since it is a specific operational/clinical update that is not a full financial report, and it is not a transcript (CT) or a presentation (IP), it best fits the general category for regulatory announcements that convey material, non-financial news, which aligns most closely with Regulatory Filings (RNS) as a catch-all for specific, non-standard announcements, or potentially a general announcement if RNS is reserved strictly for exchange filings. Given the context of a clinical milestone announcement, RNS (Regulatory Filings) is the most appropriate classification for this type of material, non-financial news release.
2020-10-26 English
PCI Biotech: Preclinical research collaboration with big pharma ended
Regulatory Filings Classification · 99% confidence The document is a short press release dated October 21, 2020, announcing that a preclinical research collaboration between PCI Biotech and AstraZeneca has ended because AstraZeneca chose not to proceed to a definitive agreement. It discusses the outcome of a collaboration, scientific know-how gained, and future plans. This type of announcement, detailing a specific business event (termination of a partnership) that is not a standard financial report (like 10-K, IR, ER), nor a management change (MANG), nor a transaction in own shares (POS), nor a dividend announcement (DIV), fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). Given the content is a specific corporate update/news release, RNS is the most appropriate classification.
2020-10-21 English
PCI Biotech: Employee share option scheme
Remuneration Information Classification · 99% confidence The document announces the award of share options to key employees and details the allocation to primary insiders (CEO, CFO, CMO, etc.). This type of announcement, detailing insider transactions related to equity compensation, most closely aligns with the 'Director's Dealing' category (DIRS), which covers personal share transactions by directors and executives, although this specific case is about options granted as part of an incentive scheme. However, looking at the provided definitions, none perfectly capture 'Employee Share Option Grant'. Since it involves executive compensation and insider holdings changes, it is related to management/director activity. If we strictly adhere to the definitions: 1. It is not an AGM-R, 10-K, AR, CT, CAP, DVA, DLST, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, RNS, DEF 14A, RPA, SHA, or POS. 2. It is not a standard Director's Dealing (DIRS) which usually reports the *sale/purchase* of existing shares, but it details options granted to insiders. 3. It is not a Management Information (MANG) announcement, which focuses on board/management *changes*. Given the options, the closest fit that deals with executive/insider equity transactions is DIRS (Director's Dealing). However, since this is a grant of options, which is a form of compensation, and it directly impacts insider holdings, it is a specific type of insider transaction disclosure. In many regulatory contexts, option grants to insiders are disclosed alongside insider trading. Since DIRS is the only category related to insider transactions, I will select it, acknowledging the slight mismatch, but it is far more relevant than other categories. If 'DEF 14A' (Remuneration Information) were broader, it might fit, but DEF 14A is usually for the full proxy statement detailing compensation philosophy. DIRS is the best fit among the provided codes for an announcement detailing executive equity awards.
2020-10-06 English
PCI Biotech: Capital increase registered and listing of new shares
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces a 'Capital increase registered and listing of new shares' following the exercise of employee share options. It details the completion of the share capital increase, the new total share capital, and the expected trading date for the new shares. This directly relates to changes in the company's capital structure and share count, matching the definition for Capital/Financing Update (CAP). Although it involves shares, it is not a general share repurchase (POS) but a specific financing/capital structure event resulting from option exercises.
2020-09-08 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists future dates for various corporate events, including 'Quarterly Report - Q3', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, but rather a schedule of upcoming corporate disclosures and events. Since it is a schedule/calendar and doesn't fit neatly into the specific categories for reports (10-K, IR, ER) or meetings (AGM-R), it functions as a general announcement regarding future corporate activities and reporting timelines. Given the options, this type of forward-looking schedule announcement is best categorized as a general Regulatory Filing (RNS) or potentially a miscellaneous announcement, as it doesn't directly correspond to a specific report type or action listed in the definitions (like DIV, DIRS, etc.). It is a communication about future reporting events.
2020-09-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.